Products Brodalumab was approved in Japan in 2016 (Lumicef) and in the United States and EU in 2017 as a solution for injection (Siliq, Kyntheum). Structure and properties Brodalumab is an IgG2κ monoclonal antibody with a molecular weight of 144 kDa, consisting of 1312 amino acids. It is produced by biotechnological methods. Effects Brodalumab (ATC … Brodalumab
Products Brolucizumab was approved as a solution for injection in the United States in 2019 and in many countries in 2020 (Beovu). Structure and properties Brolucizumab is a humanized monoclonal antibody fragment with a single Fv chain (single-chain antibody fragment, scFv). The molecular mass is in the range of 26 kDa. It is significantly lower … Brolucizumab
Products Natalizumab is commercially available as a concentrate for the preparation of an infusion solution (Tysabri). It has been approved in many countries since 2007. Structure and properties Natalizumab is a recombinant and humanized IgG4ϰ antibody produced in mouse cells that binds to α4-integrins. Effects Natalizumab (ATC L04AA23) has selective immunosuppressive properties. The effects are … Natalizumab
Products Isatuximab was approved in many countries, in the EU, and in the United States in 2020 as a concentrate for the preparation of an infusion solution (Sarclisa). Structure and properties Isatuximab is a chimeric monoclonal antibody derived from IgG1. It is produced by biotechnological methods. The molecular mass is approximately 148 kDa. Effects Isatuximab … Isatuximab
Products Dinutuximab was approved in the United States and the EU in 2015 as a concentrate for the preparation of an infusion solution (Unituxin). It has not yet been registered in many countries. Structure and properties Dinutuximab is a chimeric monoclonal antibody (human/mouse). Effects Dinutuximab (ATC L01XC16) has cytotoxic properties. It binds to ganglioside GD2, … Dinutuximab
Products Ixekizumab was approved in the United States, the EU, and many countries in 2016 as a solution for injection in a prefilled pen and syringe (Taltz). Structure and properties Ixekizumab is a humanized IgG4 monoclonal antibody with a molecular mass of 146 kDa produced by biotechnological methods. Effects Ixekizumab (ATC L04AC13) has immunosuppressive and … Ixekizumab
Products Eptinezumab is in the development phase and is not yet commercially available. Structure and properties Eptinezumab is an IgG1 monoclonal antibody directed against CGRP. Effects Eptinezumab reduces the number of migraine attacks. The effects are due to binding of the antibody to CGRP, the calcitonin gene-related peptide. CGRP is a neuropeptide that plays an … Eptinezumab
Products Tocilizumab is commercially available as a concentrate for the preparation of an infusion solution and as a solution for injection in a prefilled syringe and in a prefilled pen (Actemra, RoActemra in some countries). It has been approved in many countries since 2008. Structure and properties Tocilizumab is a recombinant humanized IgG1 monoclonal antibody … Tocilizumab
Products Adalimumab is commercially available as a solution for injection (Humira). It was approved in the United States in 2002 and in many countries and the EU in 2003. Biosimilars are available in many countries. Structure and properties Adalimumab is a human IgG1 monoclonal antibody against TNF-alpha. It is composed of 1330 amino acids and … Adalimumab Effects and Side Effects
Products Bezlotoxumab was approved in the United States and EU in 2016 and in many countries in 2017 as a concentrate for the preparation of an infusion solution (Zinplava). Structure and properties Bezlotoxumab (ATC J06BB21) is an IgG1 monoclonal antibody with a molecular weight of 148.2 kDa. It is produced by biotechnological methods. Effects Bezlotoxumab … Bezlotoxumab
Products Canakinumab is commercially available as a powder for solution for injection (Ilaris). It has been approved in many countries since 2009. Structure and properties Canakinumab is a recombinant human IgG1κ monoclonal antibody produced by biotechnological methods. Effects Canakinumab (ATC L04AC08) has anti-inflammatory properties. The effects are based on binding to interleukin-1β (IL-1β). This reduces … Canakinumab
Products Panitumumab is commercially available as an infusion solution (Vectibix). It has been approved in many countries since 2008. Structure and properties Panitumumab is a recombinant, fully human IgG2 monoclonal antibody against EGFR. Effects Panitumumab (ATC L01XC08) has antitumor and antiangiogenic properties. The effects are due to binding to the epidermal growth factor receptor (EGFR). … Panitumumab